Takeda wins label expansion for subcutaneous Entyvio, creating ‘flexibility’ for Crohn’s patients

Pa­tients tak­ing Take­da’s En­tyvio for Crohn’s dis­ease will now have the op­tion of a sub­cu­ta­neous ver­sion.

Take­da an­nounced the la­bel ex­pan­sion on Fri­day, sev­er­al months af­ter win­ning a first ap­proval for the sub­cu­ta­neous for­mu­la­tion in ul­cer­a­tive col­i­tis. En­tyvio, or vedolizum­ab, was orig­i­nal­ly ap­proved as an in­tra­venous drug in 2014 and ad­min­is­tered via a rough­ly 30-minute-long in­fu­sion.

The new for­mu­la­tion is tak­en as a main­te­nance ther­a­py fol­low­ing in­duc­tion with IV En­tyvio. It’s a sin­gle-dose, pre­filled pen, to be self-ad­min­is­tered “at home or on the go,” Take­da’s US gas­troen­terol­o­gy busi­ness unit head Bran­don Monk said in a news re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.